News

Ensysce Biosciences' PF614-MPAR, could be the industry's first overdose protection pain product, now entering a final Phase 1 study with Quotient Sciences.

John McDermott, Vice President of Scientific Consulting at Quotient Sciences, contributes to recent roundtable article with Drug Development & Delivery on 2023 trends.

Dr. Sarah Stevens, Senior Vice President & Head of Early Development & Late-Stage Commercial at Quotient Sciences, recently spoke with Raman Sehgal, host of the Molecule to Market podcast, about her career in the pharmaceutical industry and the differentiated drug development services that Quotient Sciences offers to customers.

HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company focusing on novel multifunctional therapeutics for metabolic and digestive diseases, and Quotient Sciences, a drug development and manufacturing accelerator, have signed an agreement to support HighTide’s HTD1801 program.

Quotient Sciences Celebrates Grand Opening of New Drug Substance Facility with Official Ribbon Cutting at our Alnwick facility.

Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure’s First Clinical Pharmacokinetic Study for EMPLI03.